Malignant mesothelioma is an aggressive, treatment-resistant tumour, which is increasing in
frequency throughout the world. Although the main risk factor is asbestos exposure, a virus …

In late 1993 and early 1994, two distinct lines of research converged on a new tumor
suppressor gene located on human chromosome 9p21. The órst report was of the existence …

Objectives Differentiating malignant pleural mesothelioma (MPM) from reactive mesothelial
hyperplasia (RMH) is still challenging. Detection of homozygous deletion (HD) of 9p21 …

About 80% of malignant mesotheliomas (MM) in the Western World develop in individuals
with higher than background exposure to asbestos. Only a fraction of those exposed to …

Malignant mesothelioma is an aggressive malignancy related to asbestos and erionite
exposure. AP-1 transcriptional activity and the NF-κB signaling pathway have been linked to …

Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA
methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under …

In the present study, we analyzed genomic alterations of BRCA 1‐associated protein 1
(BAP1) in 23 malignant mesotheliomas (MM s), 16 epithelioid and seven non‐epithelioid …

Aza-2'-deoxycytidine (5-AZA-CdR, Decitabine) is a nucleoside analog and an active drug for
the therapy of acute leukemia. The incorporation of 5-AZA-CdR into DNA blocks DNA …

Respiratory exposure to asbestos fibers has been associated with diffuse malignant
mesothelioma (DMM) in humans. Despite advancements in the molecular analyses of …

Exposure to the carcinogen asbestos is considered to be a major factor contributing to the
development of most malignant mesotheliomas (MMs). We highlight the role of asbestos in …